Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 17:16:1567312.
doi: 10.3389/fphar.2025.1567312. eCollection 2025.

NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals

Affiliations
Review

NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals

Xiao-Peng Zhao et al. Front Pharmacol. .

Abstract

Doxorubicin (DOX) has received widespread attention as a broad-spectrum antitumor drug. However, it has been a recognized challenge that long-term DOX injections can lead to severe cardiotoxicity. There are numerous interventions to DOX-induced cardiotoxicity, and the most cost-effective is phytochemicals. It has been reported that phytochemicals have complex and diverse biological properties, facilitating the mitigation of DOX-induced cardiotoxicity. DOX-induced cardiotoxicity has numerous pathological mechanisms, and the nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome-mediated cardiomyocyte pyroptosis is one of them. This review initially presents an overview of the pathological mechanisms that underlie cardiotoxicity induced by DOX. Subsequently, we present a comprehensive elucidation of the structure and activation of the NLRP3 inflammasome. Finally, we provide a detailed summary of phytochemicals that can mitigate DOX-induced cardiotoxicity by influencing the expression of the NLRP3 inflammasome in cardiomyocytes.

Keywords: DOX-induced cardiotoxicity; NLRP3 inflammasome; myocardial injury; phytochemicals; pyroptosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The main pathological mechanisms of doxorubicin-induced cardiotoxicity. Doxorubicin-induced cardiotoxicity involves multiple pathological mechanisms. The main can include oxidative stress, apoptosis, ferroptosis, pyroptosis, autophagy, inflammation, endoplasmic reticulum stress, epigenetics, Ca2+ overload, disturbed energy metabolism and mitochondrial dysfunction (Created with BioRender.com).
FIGURE 2
FIGURE 2
The activation process of NLRP3 inflammasome. The activation of NLRP3 inflammasome depends on two main signals. First is the “priming” signal. This signal is primarily mediated by a variety of PRRs, including TLRs. These receptors recognize PAMPs or DAMPs, thereby triggering the nuclear translocation of NF-κB. This process subsequently induces the transcription of NLRP3, IL-1β, and IL-18. The next is the “triggering” signal. The signal promotes NLRP3 oligomerization and NLRP3 interacts with ASC. ASC binds to pro-caspase-1 to form the NLRP3 inflammasome. Pro-caspase-1 is cleaved into active caspase-1, which activates pro-IL-1β, pro-IL-18 and GSDMD. Activated NT-GSDMD forms membrane pores, releasing IL-1β and IL-18 and inducing pyroptosis. This signal is triggered by factors like ion flow (K+ efflux, Na+ influx), ATP, pore-forming toxins, particulate matter and silica crystals (Created with BioRender.com). (PRRs, pattern recognition receptors; PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; TLRs, toll-like receptors; NF-κB, nuclear factor kappa B; IκK, IkappaB kinase; IL-1β, interleukin-1beta; NLRP3, nod-like receptor family pyrin domain-containing 3; ASC, apoptosis-associated speckle-like protein; GSDMD, gasdermin-D; ATP, adenosine triphosphate; P2X7, purinergic 2X7).

Similar articles

Cited by

References

    1. Abbate A., Toldo S., Marchetti C., Kron J., Van Tassell B. W., Dinarello C. A. (2020). Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126 (9), 1260–1280. 10.1161/circresaha.120.315937 - DOI - PMC - PubMed
    1. Abushouk A. I., Ismail A., Salem A. M. A., Afifi A. M., Abdel-Daim M. M. (2017). Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomed. Pharmacother. 90, 935–946. 10.1016/j.biopha.2017.04.033 - DOI - PubMed
    1. Agudelo D., Bourassa P., Bérubé G., Tajmir-Riahi H. A. (2014). Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: structural features and biological implications. Int. J. Biol. Macromol. 66, 144–150. 10.1016/j.ijbiomac.2014.02.028 - DOI - PubMed
    1. Ai Y., Yan B., Wang X. (2021). The oxidoreductases POR and CYB5R1 catalyze lipid peroxidation to execute ferroptosis. Mol. Cell Oncol. 8 (2), 1881393. 10.1080/23723556.2021.1881393 - DOI - PMC - PubMed
    1. Andreeva L., David L., Rawson S., Shen C., Pasricha T., Pelegrin P., et al. (2021). NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation. Cell 184 (26), 6299–6312.e22. 10.1016/j.cell.2021.11.011 - DOI - PMC - PubMed

LinkOut - more resources